Pfenex and Hospira have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection). Read the full story
Pfenex and Hospira have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection). Read the full story
Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, Read the full story
The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story
Hospira is a top pharmaceutical company based in Illinois, USA. Read the full story
Hospira has announced 7 M&A deals since 2005, with the lead deals being the acquisition of Mayne Pharma in 2006 and Orchid Chemicals and Pharma in 2010. Read the full story
Hospira is a big pharma company with headquarters in the USA. The company is the leading provider of injectable drugs and infusion technologies. Read the full story
Chicago based Hospira is a specialist provider of generic injectables and infusion technologies in the healthcare industry. Read the full story
Hospira, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story
Hospira acquisition would provide an acquirer with ready entry to generics pharma sector Read the full story
Hospira and Q Core Medical signed a pharma partnering distribution agreement for the Q Core Sapphire multi-therapy infusion system. Read the full story